The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection
Kinin is an important mediator of hyperalgesia, inflammatory conditions and asthma. It causes pain, inflammation, increased vascular permeability and vasodilatation. Several kinin antagonists have been developed with the aim of treating these pathologies. Kinin B2 receptor agonists and kallikrein may have clinical utility in the treatment of hypertension, left ventricular hypertrophy, ischemic heart disease, congestive heart failure and diabetes. However, there is a need to know whether there is a safe therapeutic window between potential cardio-protective and pro-inflammatory effects following administration of kinin B2 receptor agonists.
Key wordsKinin kallikrein inflammatory reactions kinin receptor antagonist kinin receptor agonist hypertension left ventricular hypertrophy diabetes
Unable to display preview. Download preview PDF.
- Chao, J. and Chao, L. (1998). Kallikrein gene therapy in hypertension, cardiovascular and renal diseases, Gen. Ther. Mol. Biol. 1, 301–308.Google Scholar
- Kichuck, M. R., Seyedi, N., Zhang, X., et al. (1996). Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation, Circulation 94, 44–51.Google Scholar
- Koide, A., Zeitlin, I. J. and Parratt, J. R. (1993). Kinin formation in ischemic heart and aorta of anaesthetized rats, J. Physiol. 467, 125P.Google Scholar
- Linz, W., Wiemer, G. and Scholkens, B. A. (1993). Bradykinin prevents left ventricular hypertrophy in rats, J. Hypertens. 11(Suppl. 5), S96–S97.Google Scholar
- Locherner, W. and Parratt, J. R. (1966). A comparison of the effects of locally and systematically administration of kinin on coronary blood flow and myocardial metabolism, Br. J. Pharmacol. Chemother. 26, 17–26.Google Scholar
- Morgolius, H. S., Geller, A., de Jong, W., et al. (1972). Altered urinary kallikrein excretion in rats hypertension, Circ. Res. 30, 358–362.Google Scholar